NanoViricides sets up at-the-market stock offering with D. Boral Capital

NanoViricides, Inc. entered into an At Market Issuance Sales Agreement on July 17, 2026 with D. Boral Capital LLC, allowing the company to offer and sell shares of its common stock from time to time through the sales agent in an "at the market" offering as defined under Rule 415(a)(4) of the Securities Act of 1933.¹

That same day, the company filed a related prospectus supplement tied to its existing shelf registration statement. The registration statement, filed under File No. 333-296550, was initially submitted to the SEC on June 5, 2026 and became effective on June 15, 2026.¹

Under the arrangement, shares may be sold through any method considered an "at the market" offering, including direct sales on the NYSE American or other existing trading markets for the stock.¹ The sales agent also has the option to arrange privately negotiated sales, but only with the company's prior written consent.¹

Each sale will be governed by placement notices that specify the parameters for how shares are to be sold under the agreement.¹ The sales agent is expected to apply its standard trading and sales practices, in compliance with applicable law, when executing sales under the agreement.¹

As compensation, NanoViricides will pay D. Boral Capital a fee set at two percent of the gross proceeds generated from each share sale completed through the arrangement.

The offering will end once all shares authorized under the agreement have been sold, or earlier if either party terminates the agreement under its terms.

Legal opinion on the validity of the shares that may be issued was provided by Lucosky Brookman LLP, filed as an exhibit to the filing.